CA
NZ
UK
AU
IND
US
…
PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic atrophy; and VP-001 for the treatment of retinitis pigmentosa type 11. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
PYC Therapeutics Ltd is an Australia-based biotechnology company developing peptide-linked nucleic acid therapeutics for rare genetic diseases and reports a pipeline that includes preclinical and clinical-stage programs. Long-term growth drivers include clinical and regulatory progress, validation of its delivery technology, and partnerships or licensing that could support commercialization, which may appeal to investors seeking exposure to oligonucleotide delivery platforms.
Key risks include clinical and regulatory setbacks, constrained capital and potential dilution, execution and partnership risk, and competition from larger oligonucleotide developers.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Income before tax | -69.76M | -51.01M | -55.67M | -23.36M | -14.29M |
| Minority interest | 0.43M | 0.71M | 0.39M | 0.57M | 0.43M |
| Net income | -43.34M | -50.30M | -37.73M | -22.79M | -14.33M |
| Selling general administrative | 6.69M | 7.07M | 4.51M | 2.54M | 4.38M |
| Gross profit | -1.20M | 23.49M | 22.06M | 15.81M | - |
| Reconciled depreciation | 0.60M | 0.60M | 0.60M | 0.55M | 0.84M |
| Ebit | -82.67M | -53.63M | -55.62M | -23.33M | -14.26M |
| Ebitda | -81.47M | -52.88M | -54.55M | -22.78M | -13.42M |
| Depreciation and amortization | 1.20M | 0.75M | 1.07M | 0.55M | 0.84M |
| Operating income | -82.67M | -53.63M | -38.86M | -23.43M | -14.26M |
| Other operating expenses | 82.67M | 77.12M | 60.92M | 39.22M | 30.21M |
| Interest expense | 0.04M | 0.06M | 0.05M | 0.03M | 0.03M |
| Tax provision | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Interest income | 13.68M | 2.68M | 0.80M | 0.08M | 0.02M |
| Net interest income | 13.64M | 2.61M | 0.75M | 0.05M | -0.01M |
| Income tax expense | -25.99M | -23.49M | -17.56M | -0.57M | 0.03M |
| Total revenue | - | 23.49M | 22.06M | 15.81M | 16.07M |
| Total operating expenses | 81.47M | 77.12M | 60.92M | 39.16M | 30.21M |
| Cost of revenue | 1.20M | - | 1.07M | - | - |
| Total other income expense net | 12.91M | 2.61M | -16.81M | 15.75M | -0.03M |
| Net income from continuing ops | -43.77M | -51.01M | -38.11M | -23.36M | -14.29M |
| Net income applicable to common shares | - | -50.30M | -37.73M | -22.79M | -13.86M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Total assets | 708.52M | 183.28M | 91.24M | 37.17M | 45.35M |
| Intangible assets | 3.65M | 3.85M | - | 4.25M | 4.45M |
| Other current assets | 0.55M | 0.41M | 0.74M | 0.05M | 0.07M |
| Total liab | 15.18M | 13.27M | 10.18M | 8.72M | 5.15M |
| Total stockholder equity | 693.33M | 169.57M | 80.50M | 27.75M | 39.35M |
| Other current liab | 4.16M | - | 1.27M | 3.49M | 1.81M |
| Common stock | 933.25M | - | 230.58M | 140.09M | 125.99M |
| Capital stock | 933.25M | 369.59M | - | 140.09M | 125.99M |
| Retained earnings | -249.54M | -206.20M | -155.89M | -118.17M | -95.38M |
| Other liab | - | - | - | 0.18M | 0.08M |
| Other assets | - | - | - | 0.00M | 0.02M |
| Cash | 53.56M | 153.05M | 66.87M | 15.57M | 29.11M |
| Cash and equivalents | - | - | - | 15.57M | 29.11M |
| Total current liabilities | 14.40M | 12.32M | 9.11M | 8.41M | 4.39M |
| Current deferred revenue | - | - | - | -0.18M | -0.26M |
| Net debt | -52.94M | - | -65.76M | -15.26M | -28.17M |
| Short term debt | 0.36M | - | 0.31M | 0.18M | 0.26M |
| Short long term debt total | 0.62M | - | 1.11M | 0.32M | 0.94M |
| Other stockholder equity | - | - | - | -21.92M | -30.61M |
| Property plant equipment | - | - | - | 1.04M | 1.63M |
| Total current assets | 482.23M | 177.53M | 85.61M | 31.87M | 39.25M |
| Long term investments | 221.20M | - | - | - | - |
| Net tangible assets | - | - | - | 23.50M | 34.90M |
| Short term investments | 394.00M | - | - | - | 0.00M |
| Net receivables | 34.13M | - | 18.00M | 16.25M | 10.07M |
| Accounts payable | 9.89M | 8.75M | 7.53M | 4.92M | 2.57M |
| Accumulated other comprehensive income | 9.62M | - | 5.81M | 5.83M | 8.74M |
| Non currrent assets other | - | - | 4.05M | -5.29M | 0.02M |
| Non current assets total | 226.28M | 5.75M | 5.62M | 5.29M | 6.10M |
| Capital lease obligations | 0.62M | 1.02M | - | 0.32M | 0.94M |
| Long term debt total | - | - | - | 0.14M | 0.68M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-06-30 | 2023-06-30 | 2022-06-30 |
| Investments | -615.63M | -0.98M | -0.31M | -0.48M | 33.07M |
| Change to liabilities | - | - | - | 4.34M | 0.26M |
| Total cashflows from investing activities | -616.16M | -0.98M | -0.31M | -0.48M | 32.68M |
| Net borrowings | - | - | - | -0.23M | -0.18M |
| Total cash from financing activities | 563.22M | 138.66M | 90.19M | 11.44M | -0.18M |
| Change to operating activities | - | - | - | -0.14M | 0.53M |
| Net income | -43.34M | -50.30M | -37.73M | -22.79M | -13.86M |
| Change in cash | -99.49M | 86.18M | 51.30M | -13.54M | 10.67M |
| Begin period cash flow | 153.05M | 66.87M | 15.57M | 29.11M | 18.44M |
| End period cash flow | 53.56M | 153.05M | 66.87M | 15.57M | 29.11M |
| Total cash from operating activities | -44.52M | -51.56M | -38.59M | -24.42M | -21.78M |
| Issuance of capital stock | 600.22M | 145.82M | 92.06M | 12.65M | - |
| Depreciation | 1.20M | - | 1.07M | 0.88M | 0.84M |
| Other cashflows from investing activities | - | - | 0.00M | 0.01M | 33.07M |
| Change to account receivables | -10.20M | -5.74M | -2.44M | -6.16M | -9.83M |
| Sale purchase of stock | -36.61M | -6.80M | -1.57M | -0.98M | -0.98M |
| Other cashflows from financing activities | -0.40M | -6.80M | -0.29M | -0.23M | -0.18M |
| Change to netincome | - | - | - | -0.55M | 0.18M |
| Capital expenditures | 0.53M | 0.98M | 0.31M | 0.49M | 0.39M |
| Change in working capital | -7.89M | -2.56M | -2.16M | -6.16M | -9.83M |
| Stock based compensation | - | - | 0.25M | -0.07M | 0.61M |
| Other non cash items | 5.51M | -49.00M | 0.23M | -2.51M | -8.76M |
| Free cash flow | -45.05M | -52.54M | -38.90M | -24.91M | -22.17M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| PYC PYC Therapeutics Ltd |
-0.05 2.59% |
1.88 | - | 12.00 | 73.11 | 2.63 | 25.02 | -8.41 |
| CSL CSL Ltd |
-0.36 0.18% |
202.04 | - | 22.57 | 6.15 | 4.48 | 4.82 | 10.06 |
| TLX TELIX Pharmaceuticals Ltd |
-0.41 2.91% |
13.67 | 93.87 | 166.67 | 5.37 | 6.37 | 3.85 | 47.29 |
| NEU Neuren Pharmaceuticals Ltd |
- -% |
23.24 | 154.93 | 36.36 | 42.38 | 7.52 | 31.95 | 160.40 |
| MSB Mesoblast Ltd |
-0.14 6.45% |
2.03 | - | 454.55 | 23.43 | 3.36 | 18.28 | -9.86 |
PYC Therapeutics Limited, a clinical stage drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. It is developing PYC-003, which is in Phase1a/1b multiple ascending dose study for polycystic kidney disease; PYC-002, a Phelan McDermid Syndrome; PYC-001 for the treatment of Phelan-McDermid Syndrome; PYC-001, which is in Phase 1b multiple ascending dose study for autosomal dominant optic atrophy; and VP-001 for the treatment of retinitis pigmentosa type 11. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
Harry Perkins Institute of Medical Research, Nedlands, WA, Australia, 6009
61 8 6151 0992
| Name | Title | Year Born |
|---|---|---|
| Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.) | CEO & Exec. Director | 1983 |
| Mr. Andrew Taylor B.Com., C.A. | Chief Financial Officer | NA |
| Prof. Sue Fletcher | Chief Scientific Officer | NA |
| Dr. May Orfali M.B.A., M.D. | Chief Medical Officer of US Operations | 1968 |
| Dr. Glenn Noronha | Chief Devel. Officer | 1965 |
| Mr. Kevin Ronald Hart B.Com, B.Comm (Hons), C.A., F.C.A., FCA | Company Sec. | 1962 |
| Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.) | CEO & Executive Director | 1983 |
| Mr. Andrew Taylor B.Com., C.A. | CFO & Company Secretary | NA |
| Mr. Kevin Ronald Hart B.Com., B.Comm (Hons), C.A., F.C.A. | Company Secretary | 1962 |
| Dr. Rohan Hockings G.D.L.P, J.D., MBBS, MBBS (Hons.) | CEO & Executive Director | 1983 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+0.61%
Communication Services
-0.21%
Consumer Cyclical
-0.26%
Consumer Defensive
-0.37%
Energy
+0.23%
Financial Services
-0.43%
Financials
+0.39%
Healthcare
+0.88%
Industrials
+0.36%
Real Estate
-0.51%
Technology
+1.35%
Utilities
+0.19%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...